tbuckley/cabot-search huggingface dataset:
β-Carotene as an Oral Photoprotective Agent in Erythropoietic Protoporphyria
Authors: Micheline M. Mathews-Roth
Journal: JAMA (1974)

Fifty-three patients having erythropoietic protoporphyria (EPP), with elevated levels of prophyrins in blood and feces and with photosensitivity after exposure to sunlight or artificial light, were treated with β-carotene given orally in dosages ranging from 15 to 180 mg/day. After treatment, 46 patients increased by fourfold or more the time they could tolerate exposure to sunlight without discomfort, and three have doubled their exposure time. Three patients were doubtful that any improvement had occurred and one had no improvement. No untoward side effects were noted in toxicity studies of the patients. There was no evidence of hypervitaminosis A or of leukopenia. Thus, the oral administration of high doses of β-carotene is a safe and effective method of ameliorating in most patients the photosensitivity that occurs in EPP. (<i>JAMA</i>228:1004-1008, 1974)
PHOSPHORYLATED CARDIAC MYOSIN BINDING PROTEIN-C ENHANCES LUSITROPY
Authors: Paola Cecilia Rosas, Yang Liu, Mohamed Abdalla, Candice Thomas, David Kidwell, Rajesh Kumar, Kenneth Baker, Bindiya Patel, Chad Warrens, R. Solaro, Patricia Powers, Richard Moss, Carl Tong
Journal: Journal of the American College of Cardiology (2014)
Abstract 5619: Natural killer cell function in multiple myeloma is impaired by dexamethasone and can not be rescued by immunomodulatory drugs
Authors: Andy Hsu, Hang Quach, Tsin Tai, H M. Prince, Mark J. Smyth, Joseph A. Trapani, Paul J. Neeson, David S. Ritchie
Journal: Cancer Research (2010)

Abstract The immunomodulatory (IMiD) drug Lenalidomide (Len) is known to stimulate natural killer (NK) cells and enhance anti-tumor responses. Len plus Dexamethasone (Dex) therapy (Len-Dex) is an effective treatment for multiple myeloma (MM). As part of a prospective clinical trial of monthly cycles of Len-Dex therapy we assessed NK cell number and function in 25 MM patients. Whilst NK numbers increased from a mean of 2×105/ml (baseline) to a mean of 3.9×105/ml (cycle 6) (p=0.05), the mean NK cell-mediated cytotoxicity in chromium assays against K562 significantly decreased from 48.9% to 27.6% respectively (p=0.0028). Further analysis showed that when NK cell cytotoxicity was assessed from MM patient peripheral blood mononuclear cells (PBMC) during therapy, no enhancement of cytotoxicity could be observed when cultured in vitro with Len. We hypothesized that Dex potently suppressed the Len-mediated enhancement of NK function. In vitro, Len increased normal donor (n=6) NK cytotoxicity from 38.5% (untreated) to 53.3%. Dex severely impaired NK cytotoxicity to &amp;lt;10%, this failed to increase (&amp;lt;13%) in the presence of Len. Only the addition of high dose IL-2 (500U/ml) rescued cytotoxicity of Dex-treated NK cells (28.6%). The suppressive effect of Dex on NK cytotoxicity was not permanent as NK function returned to normal levels within 3 days of drug removal. However, these dex-‘washout’ PBMCs could no longer respond to Len with increased NK function, suggesting a permanent Dex-induced NK impairment. In cell sorting and co-culture experiments we found that Len enhancement of NK cytotoxicity was only mediated by CD4+ T cells (NK alone 76.6% vs NK+CD4 85%) and the effect of CD4+ T cells was IL-2 dependent. Furthermore IL-2 production by CD4+ T cells in response to anti-CD3/CD28 was also suppressed by Dex. Following Len-Dex therapy in patients we observed less IL-2 and IFN-γ production from T cells in response to anti-CD3/CD28 at cycle 6 compared to baseline. Therefore, Len-mediates enhanced NK function through CD4+ T cell production of IL-2. The NK impairment observed in MM patients receiving Len-Dex is due to CD4+ T cell suppression. Our findings indicate that in order to harness both the anti-tumor and immunomodulatory capacity of Len the dose and timing of Dex therapy should be carefully reconsidered. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5619.
F-18 FDG Uptake in Papillary Carcinoma Arising From Thyroglossal Duct Cyst
Authors: Cheng-Ping Wang, Yu-Chien Shiau, Ruoh-Fang Yen
Journal: Clinical Nuclear Medicine (2011)

A 51-year-old man incidentally felt an anterior midline cervical mass since 2 months before presentation. Both neck echogram and contrast-enhanced CT exposed a cystic lesion with slightly calcified soft tissue in anterior neck and small nodules in both lobes of the thyroid gland. F-18 FDG PET/CT revealed an intense uptake over the soft-tissue component of the cystic lesion, which was located in front of the hyoid bone. The patient subsequently received Sistrunk procedure, selective neck lymph node dissection, and total thyroidectomy. Pathology revealed papillary carcinoma in thyroglossal duct cyst and microcarcinoma in both lobes of the thyroid gland.
ABC of 1 to 7: Acute abdominal pain.
Authors: H B Valman
Journal: BMJ (1981)

ABC of 1 ~~~to7 H BVAINAt the beginning of an episode of abdominal pain it may be difficult to .... ~~~~~make an exact diagnosis.The picture will become clearer if the child is ~~~~~seen again after a few hours, but if this is not possible the child may have to be admitted to hospital for observation.Many parents are worried that b ~~~~~~~their child has acute appendicitis, and the responsibility for keeping an eye 95* ~~~~~~on the child should not be left to the parents, who do not have the ~~~knowledge to make the right judgments.Although a definite diagnosis should be attempted it is essential to place the patient in one of the following groups: :,: ...... ..... ~~~(a) surgical problem: admit; ~(b) chronic medical problem: admit or arrange paediatric appointment;(c) gastroenteritis: manage at home or admit to an isolation cubicle of the paediatric unit depending on the severity of the illness; (d) cause uncertain: see again within a few hours or admit to hospital for observation.
Double ventricular parasystole. Supernormal phase of conduction as a mechanism of intermittent parasystole. Report of a case.
Authors: K Hiejima, T D Poh
Journal: Circulation (1976)

A rare case of spontaneous double ventricular parasystole was studied in depth, together with a critical review of similar cases in the literature. The discussion was focused on 1) the variation of the shortest interectopic interval (SIEI), 2) entrance block and its failure, 3) supernormality as a mechanism of intermittence, and 4) effects of lidocaine and atropine on such an arrhythmia. In double ventricular parasystole a greater than usual variation in the SIEI tended to occur in one of the two parasystolic groups. If, however, such variations were too great in the face of otherwise parasystolic rhythm, presence of intermittence was confirmed. A temporary loss of the entrance block was deemed primarily responsible for the intermittency. That is to say, invasion, discharge, and resetting of one parasystolic focus by another parasystolic impulse during the supernormal phase of the ventricle was considered the cause of an intermittence. In a strict sense, this is the first report in the literature in which the supernormality was clearly indicated as one mechanism of intermittent ventricular parasystole. The advantage of the concept of double ventricular parasystole as compared to single parasystole in defining such a mechanism is stressed.
Post-insult treatment with interleukin-1 receptor antagonist decreases oxidative lung injury in rats given intratracheal interleukin-1.
Authors: J A Leff, M E Bodman, O J Cho, S Rohrbach, O K Reiss, J L Vannice, J E Repine
Journal: American Journal of Respiratory and Critical Care Medicine (1994)

Systemic administration of recombinant human interleukin-1 receptor antagonist (IL-1Ra) caused a rapid and sustained elevation of plasma IL-1Ra levels and decreased the leak of intravascularly injected 125I-labeled albumin into lungs of rats given human recombinant interleukin-1 intratracheally. IL-1Ra treatment decreased leak when given 0.5 h before, 1.25 h after, or 2.5 h after IL-1 administration. Similarly, IL-1Ra treatment decreased lavage leukocytes and neutrophils when given 0.5 h before, 1.25 h after, or 2.5 h after IL-1 administration. Pretreatment with IL-1Ra also decreased lung myeloperoxidase activity and breath H2O2 concentration increases in rats given IL-1 intratracheally. Our results suggest that IL-1Ra treatment may decrease acute lung injury and neutrophil influx even when given after an IL-1 inciting insult.
Disopyramide and Cholestasis
Authors: ANTONIO CRAXI
Journal: Annals of Internal Medicine (1980)

Letters1 July 1980Disopyramide and CholestasisANTONIO CRAXI, M.D., GATTO GIOVANNI, M.D., ALBERTO MARINGHINI, M.D., SALVATORE ORSINI, M.D., GIOVANNI PINZELLO, M.D., LUIGI PAGLIARO, M.D.ANTONIO CRAXI, M.D.Search for more papers by this author, GATTO GIOVANNI, M.D.Search for more papers by this author, ALBERTO MARINGHINI, M.D.Search for more papers by this author, SALVATORE ORSINI, M.D.Search for more papers by this author, GIOVANNI PINZELLO, M.D.Search for more papers by this author, LUIGI PAGLIARO, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-93-1-150_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Disopyramide (Norpace; G. D. Searle & Company, Chicago, Illinois) has been marketed in Europe since 1969 and has been widely accepted as an effective, well-tolerated antiarrhythmic agent. Cholestatic jaundice has been reported in at least three patients on disopyramide (1-3). Recently we have observed three more patients with cholestasis probably related to disopyramide. The relevant laboratory data are given in Table 1. The patients had no hepatosplenomegaly, fever, abdominal pain, or heart failure; tests for hepatitis B surface antigen, alpha-fetoprotein, and antimitochondrial antibodies were always negative.Patient 1 was a 63-year-old man who received, after a myocardial...References1. RICCIONIBOZZISUSINIRONI NLNP. Disopyramide-induced intrahepatic cholestasis. Lancet. 1977;2:1362-3. Letter. CrossrefMedlineGoogle Scholar2. MEINERTZLANGERKASPERJUST TKWH. Disopyramide-induced intrahepatic cholestasis. Lancet. 1977;2:828-9. Letter. CrossrefMedlineGoogle Scholar3. GOTTSCHALLCUNHAMILLER CJV. Disopyramide jaundice. Rev Assoc Med Rio Grande Sul. 1970;14:195-6. Google Scholar4. KOCH-WESER J. Drug therapy: disopyramide. N Engl J Med. 1979;300:957-62. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Instituto di Patologia Medica 3° Palermo Italy PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byFatal torsade de pointes following jaundice in a patient treated with disopyramide.9 Drug-induced cholestasisDrugs and Liver Disease: A Tabular Compilation of Drugs and the Histopathological Changes That Can Occur in the LiverAntiarrhythmic Drug Monitoring 1 July 1980Volume 93, Issue 1_Part_1Page: 150-151KeywordsAbdominal painAntimitochondrial antibodiesFeversHeart failureHepatitis B surface antigenHepatosplenomegalyResearch laboratories ePublished: 1 December 2008 Issue Published: 1 July 1980 PDF downloadLoading ...
TCT-561 Final Five-Year Outcomes Following Implantation of the Promus Element® Platinum Chromium Everolimus-Eluting Stent in De Novo Coronary Artery Lesions in Small Vessels (SV) and Long Lesions (LL): Results of the PLATINUM Small Vessel and Long Lesion Trials
Authors: Paul Teirstein, Gregg W. Stone, Ian T. Meredith, Abram C. Rabinowitz, Vincent J. Pompili, Tommy C. Lee, Louis A. Cannon, Dean J. Kereiakes, Michael Mooney, Didier Carrié, Shigeru Saito, Dominic J. Allocco, Keith D. Dawkins
Journal: Journal of the American College of Cardiology (2015)
Hepatitis B virus infection in medical and health care personnel.
Authors: M E Callender, Y S White, R Williams
Journal: BMJ (1982)

Analysis of 51 cases of hepatitis B virus infection in health care workers admitted as patients to the liver unit over seven years showed three healthy carriers of hepatitis B virus, seven cases of fulminant hepatic persistent hepatitis, 17 cases of chronic active hepatitis (of whom 11 had cirrhosis), and five cases of hepatocellular carcinoma. To date 11 of these patients have died. Only 15 of the 51 patients had a history of direct occupational exposure and only three patients could recall specific inoculation injuries. In contrast, the source of infection was apparent in 32 of 50 consecutive cases of fulminant hepatic failure or acute hepatitis B in nonmedical staff. Since specific inoculation injuries are not the usual mode of infection ion medical staff and since only a few of the patients who are hepatitis B virus carriers will be detected by selective screening of "high-risk" patients, the overall risk of infection can be reduced only by stricter precautions in the handling of any patient9s blood and by the use of hepatitis B virus vaccines for medical staff at high risk.
False-positive Radionuclide Arthroscintigraphy with a Porous-coated Total Hip Prosthesis
Authors: STEPHEN G. OSWALD, PAUL J. HERZWURM
Journal: Clinical Nuclear Medicine (1991)

The evaluation of a painful hip prosthesis for suspected loosening frequently requires a multi-modality approach. Radionuclide arthroscintigraphy is a valuable adjunct to contrast arthrography, demonstrating greater sensitivity than contrast arthrography in detecting loosening of the femoral component of the prosthesis. Despite its reliability in the evaluation of cemented hip prostheses, the value of arthroscintigraphy in patients with uncemented or porous-coated prostheses is undetermined. The case of a false-positive radionuclide arthroscintigram in a patient with an uncemented prosthesis is reported. The literature is briefly examined, and the potential implications regarding interpretation of arthroscintigraphy in patients with porous-coated prostheses are discussed.
“Right to die”: Legal view of right to life and death could threaten philosophy of palliative care
Authors: John C Chambers
Journal: BMJ (2005)

EDITOR—Grayling claims that the “right to life” means quite a rich life; withholding treatment with death as the result and giving treatment that causes death are indistinguishable; and death is the ultimate analgesic.1 Grayling also implies that the double effect is widely abused.

The EC Convention for the Protection of Human Rights and Fundamental Freedoms protects against intentional deprivation of life.2 Quality of life is not mentioned, and terminating …
Paradoxical vocal cord adduction in cystic fibrosis.
Authors: S Crowley, A Bush
Journal: Thorax (1995)

Letters to the editor look at first glance as though ICI 118 551 has no effect on exercise-induced hyperkalaemia compared with placebo.However, the base- line potassium concentration was significantly lower in the ICI 118 551 group than in the placebo group, and this may explain the ap- parent lack of effect on exercise response.Furthermore, in that study atenolol had no effect on the exercise-induced potassium re- sponse, suggesting that ,13 receptors are not involved.Indeed, in our own study sal- butamol had no effect on the exercise heart rate response, showing that PI3 blockade did not occur.It has also been shown that a low dose of nadolol (5 mg), which has a minimal P, blockade, exhibits marked P2 blockade as assessed by exercise-induced hyperkalaemia.3Thus, the fact that in our study both sal- butamol and propranolol significantly aug- mented the exercise-induced potassium response is in keeping with a P2 receptor mediator mechanism linked to the Na/K-ATPase pump.This hypothesis is further sup- ported by the enhancement of exercise-induced hyperkalaemia by digitalis which directly inhibits the Na/K-ATPase pump.4We therefore remain of the firm opinion that, in the presence of high adrenergic tone, salbutamol exhibits 12 antagonist activity as demonstrated by augmentation of exerciseinduced hyperkalaemia.This would be in keeping with the known pharmacological properties ofsalbutamol as a partial P2 agonist along with in vitro data showing salbutamol to antagonise the relaxant effect of isoprenaline in the presence of carbachol- induced bronchoconstriction.5 Whilst we agree that salbutamol is of great value in treating acute bronchospasm, it may be that a P2 agonist with greater intrinsic activity may be preferable in certain situations where airway tone is increased.
Beyond diagnosis and statistics
Authors: S. Vaisrub
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunization and Antibody Response in the Newborn Infant
Authors: R. William Provenzano, Leslie H. Wetterlow, Charles L. Sullivan
Journal: New England Journal of Medicine (1965)

THE pediatrician, general practitioner and public-health officer are concerned with early, safe, effective protection against diseases that can be prevented by the use of vaccines. The earliest time that adequate active immunization can be accomplished in infants is very difficult to determine, and in fact not finally decided for any of the immunizing agents commonly used in infancy,1 2 3 4 5 although the basic processes involved in immunology are being pursued. Previous studies6,7 showed that children at three weeks of age can be effectively immunized against pertussis, tetanus and diphtheria. These studies demonstrated that protective levels of antibody responses could be obtained . . .
Abstract 1283: Phase I and pharmacokinetic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine: A California Cancer Consortium study
Authors: Edward M. Newman, Robert J. Morgan, Jan H. Beumer, Suzette M. Blanchard, Anthony B. El-Khoueiry, Shivaani Kummar, Mary I. Carroll, Timothy W. Synold, Heinz J. Lenz, James H. Doroshow
Journal: Cancer Research (2011)

Abstract Background: The California Cancer Consortium conducted the first-in-human clinical trial of the investigational new drug 5-fluoro-2′-deoxycytidine (FdC), a DNA methyltransferase inhibitor stable in aqueous solution, as a 3-hour infusion concurrent with 350 mg/m2 of the cytidine deaminase inhibitor tetrahydrouridine (THU), included to prolong the half-life of FdC in vivo. Methods: A 3+3 design was used; initial FdC dose doubling ended when two moderate toxicities or one severe toxicity were observed. Pharmacokinetics of FdC and THU were obtained. Results: On the initial schedule, daily (QD) × 5 every 21 days (d), FdC was escalated from 2.5 to 80 mg/m2/d without treatment-related grade 3 toxicity other than anemia and lymphopenia. At FdC doses ≥20 mg/m2/d, peak plasma FdC concentrations were above those that inhibit DNA methylation in vitro (Beumer, et al., Cancer Chemother Pharmacol 62:363-8, 2008). The schedule was amended to QD × 5 for 2 consecutive weeks every 28 d, and patients (pts) were enrolled at 40, 67, 100, 134, and 180 mg/m2/d. Overall, 51 pts were treated [28 M; 23 F; median (range): age 63 (30-85), KPS 80 (60-100)]; 44 pts were evaluable for toxicity (1 cycle). 1/6 pts at 134 mg/m2/d had dose-limiting toxicity (DLT) (grade 3 colitis) and 2/2 pts at 180 mg/m2/d had DLT (1-grade 3 fatigue + LFT; 1-grade 4 mucositis + ANC + platelets). Of the 31 pts on 28-d cycles, 8 had clinical progression prior to the first scheduled evaluation at 8 weeks and 5 did not complete 2 cycles for other reasons; 7 pts had progressive disease at 8 weeks; and 10 pts had stable disease for ≥8 weeks. In addition, 1 heavily-pretreated pt with breast cancer, treated at 67 mg/m2/d, had a partial response lasting 1 year. Conclusions: The Maximum Tolerated Dose was 134 mg/m2/d FdC + 350 mg/m2/d THU QD × 5 for 2 consecutive weeks every 28 d. An expansion cohort is being accrued to determine the pharmacokinetics of oral FdC and THU. Based on the nature of the toxicities and the observed response at 67 mg/m2/d, a multi-histology Phase II trial has been initiated at 100 mg/m2/d QD × 5 for 2 consecutive weeks every 28 d. Supported by U01 CA62505, P30 CA33572, N01-CM-52202, and P30CA47904. The authors acknowledge the invaluable contribution of Dr. M. J. Egorin. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1283. doi:10.1158/1538-7445.AM2011-1283
Lancefield group C streptococcal endocarditis
Authors: P. Finnegan, M. X. M. Fitzgerald, G. Cumming, A. M. Geddes
Journal: Thorax (1974)

<b>Finnegan, P., Fitzgerald, M. X. M., Cumming, G., and Geddes, A. M. (1974).</b><i>Thorax</i>, <b>29</b>, 245-247. <b>Lancefield group C streptococcal endocarditis.</b> Three cases of endocarditis due to Lancefield group C streptococcus are reported. These organisms are of low pathogenicity and they are infrequently responsible for infection in man. The cases reported emphasize, however, that they may cause serious and fatal illness.